Real-world evidence indicates that patients with psoriasis can safely and effectively undergo (non-medical) switching to a biosimilar.
Lana Pine
Advertisement
Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at [email protected].
Articles by Lana Pine
Shifts towards on-patient and higher-cost therapies have been observed in TNF-alpha inhibitor biosimilar availability. Therefore, the importance of investing in biosimilars is encouraged.
The safety and efficacy of 4 adalimumab biosimilars was compared in a real-life setting in adult patients with IBD switching from the originator for a non-medical reason.
“The fact that patients report substituting cannabis for pain medications so much underscores the need for research on the benefits and risk of using cannabis for chronic pain,” investigators stated.
Advertisement
Advertisement
Advertisement
Trending on HCPLive
1
METRE-PL Data Shows Severe Metabolic Disease Burden in FPLD Despite Standard Therapy
2
IL-13 Inhibitor Response Can Guide Patch Testing Decisions in Eczematous Dermatitis
3
Q&A: The Pillared Approach and Reframing Goals of CKD Care, With Katherine Tuttle, MD
4
The Medical Sisterhood: The Strength Nobody Talks About, with Saakshi Khattri, MD
5